A Clinical Study on the Efficacy and Safety of Ivarmacitinib in Preventing aGVHD After HLA-matched Transplantation

NCT07381114 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

32

Enrollment

OTHER

Sponsor class

Conditions

aGVHD

Interventions

DRUG: Ivarmacitinib

Sponsor

Institute of Hematology & Blood Diseases Hospital, China